26
Participants
Start Date
May 31, 2007
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
CC-5013 (lenalidomide)
Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
dexamethasone
Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
Washington County Hospital, The Center for Clinical Research, Hagerstown
New Bern Cancer Care, New Bern
Northwestern Carolina, Oncology and Hematology PA, Hickory
Northwest Georgia Oncology Centers, Marietta
Advanced Medical Specialties, Miami
Hematology/Oncology Associates of Treasure Coast, Port Saint Lucie
University of Kentucky, Lexington
James Cancer Hospital, Columbus
Kalamazoo Hematology & Oncology, Kalamazoo
Cancer Care & Hematology Specialists of Chicagoland, Arlington Heights
Northwestern University, Feinberg School of Medicine, Chicago
Rush University Medical Center, Chicago
Southwest Oncology Associates, Lafayette
SouthWest Regional Cancer Center, Austin
Northern Utah Associates, Ogden
Palo Verde Hematology/Oncology, Ltd., Glendale
Tower Cancer Research Foundation, Beverly Hills
Oncology & Hematology Specialists, PA, Denville
Hackensack University Medical Center, Hackensack
The Alfred Hospital, Melbourne
Frankston Hospital, Frankston
HOCA, South Brisbane
Border Medical Oncology, Wodonga
Cross Cancer Institute, Edmonton
Lead Sponsor
Celgene Corporation
INDUSTRY